Pipeline

Project overview & milestone plan

The well validated research of Coegin Pharma has demonstrated that the cPLA₂α enzyme is a relevant therapeutic target for a number of cancers and inflammatory diseases, including actinic keratosis, basal cell carcinoma, leukemia, triple-negative breast cancer and chronic kidney disease.

The Company has previously established proof-of-conceptin psoriasis, which is a robust validation of the mechanism of action. The company’s development projects all derive from the same unique mechanism of action, and the Board of Directors’ assessment is that Coegin Pharma holds unique potential to develop first-in-class pharmaceuticals for the treatment of several serious diseases where current treatment options are insufficient.

Project/Indication Candidate Route of administration 2021 2022 2023
Actinic keratosis AVX001 Topical Phase I/II    
Basalcellscancer AVX001 Topical   Phase IIa  
Leukemia/breast cancer Not disclosed Systemic Pre-clinical   Pre-clinical Phase I  
Chronic kidney disease Not disclosed Systemic Pre-clinical   Pre-clinical Phase I  

Timeline

Major milestones 2021 – 2022

Year

Actinic keratosis (Phase I/II)

Basal cell carcinoma (Phase IIa) Cancer (Phase I ready) Chronic kidney disease (Phase I ready) Spinout
2021
  • Clinical application submitted Q1
  • Patient recruitment commences Q3
  • Last patient treated and followed up Q4
 
  • Candidate selected Q2
  • Pre-clinical development commences Q3
  • Candidate selected Q2
  • Pre-clinical development commences Q3
 
2022
  • Topline results Q1
  • Clinical application submitted Q1
  • Patient recruitment commences Q3
  • Last patient treated and followed up Q4
  • Topline results Q1 2023
  • Pre-clinical development completed Q2
  • Phase I ready Q4
  • Pre-clinical development completed Q2
  • Phase I ready Q4
  • “Cancer Company” Q1 
  • “Kidney Company” Q3